Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) have received an average recommendation of "Moderate Buy" from the five brokerages that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $12.20.

A number of equities research analysts have recently commented on INO shares. StockNews.com upgraded shares of Inovio Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday. HC Wainwright reaffirmed a "neutral" rating and issued a $3.00 target price on shares of Inovio Pharmaceuticals in a research note on Wednesday, March 19th. JMP Securities reissued a "market outperform" rating and set a $18.00 price target on shares of Inovio Pharmaceuticals in a research note on Friday, January 10th. Finally, Royal Bank of Canada lowered their price objective on Inovio Pharmaceuticals from $6.00 to $5.00 and set a "sector perform" rating for the company in a research report on Wednesday, March 19th.

Institutional Trading of Inovio Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its holdings in Inovio Pharmaceuticals by 6.7% in the third quarter. Geode Capital Management LLC now owns 621,631 shares of the biopharmaceutical company's stock valued at $3,594,000 after acquiring an additional 38,833 shares during the last quarter. Barclays PLC raised its holdings in shares of Inovio Pharmaceuticals by 282.6% in the 3rd quarter. Barclays PLC now owns 34,003 shares of the biopharmaceutical company's stock worth $197,000 after purchasing an additional 25,116 shares during the period. FMR LLC lifted its stake in shares of Inovio Pharmaceuticals by 370.1% in the 3rd quarter. FMR LLC now owns 27,261 shares of the biopharmaceutical company's stock valued at $158,000 after purchasing an additional 21,462 shares in the last quarter. State Street Corp grew its holdings in shares of Inovio Pharmaceuticals by 11.7% during the 3rd quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company's stock worth $2,836,000 after purchasing an additional 51,414 shares during the period. Finally, Wellington Management Group LLP acquired a new stake in Inovio Pharmaceuticals during the 3rd quarter worth approximately $379,000. 26.79% of the stock is owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Stock Performance

Shares of NASDAQ:INO opened at $1.74 on Friday. The business's fifty day moving average price is $1.87 and its two-hundred day moving average price is $3.00. The stock has a market cap of $63.80 million, a PE ratio of -0.44 and a beta of 1.84. Inovio Pharmaceuticals has a one year low of $1.42 and a one year high of $13.44.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last posted its quarterly earnings data on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) EPS for the quarter, beating analysts' consensus estimates of ($0.87) by $0.18. The company had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.03 million. As a group, equities research analysts predict that Inovio Pharmaceuticals will post -4.23 earnings per share for the current fiscal year.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.